Draupnir Bio

Draupnir Bio is founded on the pillars of outstanding protein and carbohydrate chemistry. Its mission is to understand the molecular basis of how disease-risk proteins interact with carbohydrate structures of the vascular glycocalyx, and use this knowledge to develop therapeutics for life-threatening illnesses. The lead program is a small molecule oral available PCSK9 inhibitor for lowering LDL cholesterol. Its discovery is based on the finding that PCSK9-induced degradation of the LDL receptor requires the interaction of PCSK9 with distinct heparan sulfate structures of the liver glycocalyx. Inhibition of the PCSK9/heparan sulfate interaction protects the LDL receptor and allows it to remove LDL cholesterol from the blood, thereby preventing the progression of ischemic heart disease, the biggest killer worldwide.

Contact name:

Simon Glerup CEO

Address:

Solsikkevej 8, 8240 Risskov, Denmark

Telephone:

+45 51221727

Established:

2017

Number of employees:

9

If you cannot find what you are looking for or if you have feedback to our website, please do not hesitate to contact dd@danskbiotek.dk or +45 5150 0560

Copyright 2020 Danskbiotek. All rights reserved.